The FDA has issued a safety communication warning against off-label use of the Lariat device for percutaneous closure of the left atrial appendage (LAA) for stroke prevention in A-fib patients. The ...

PHILADELPHIA - The Lariat device, which has been cleared by the U.S. Food and Drug Administration (FDA) for soft tissue approximation (placement of a suture) during surgical procedures, is associated ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--SentreHEART, Inc., announced it has successfully completed nine First-In-Human procedures utilizing the LARIAT® with EpiRAIL™ at John Paul II hospital in Krakow, ...

Until Lariat receives FDA approval specifically for LAA occlusion, its current off-label use in clinical practice “should be questioned,” says Dr. Paul Varosy. The safety signal is all the more ...

Shannon Dickson couldn’t get the words out of his mouth. On a Saturday morning, the retired engineer was at home in Sedona, Ariz., trying to talk to his wife on the phone. Dickson knew what he wanted ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--SentreHEART, Inc., the manufacturer of the LARIAT technology for catheter-based, non-implant left atrial appendage closure (LAAC), today announced it has closed ...

SentreHeart brought in $35 million in Series D financing to wrap up a critical study of its catheter-based nonimplant left atrial appendage (LAA) closure device in patients with atrial fibrillation.

The Valley Hospital in Ridgewood, NJ, is one of 15 U.S. sites currently enrolling patients in a research study to evaluate a potential new treatment alternative for patients with symptomatic ...